KAAACI Allergic Rhinitis Guidelines: Part 2. Update in nonpharmacotherapy
Allergy, Asthma & Respiratory Disease
; : 126-134, 2023.
Article
em En
| WPRIM
| ID: wpr-999247
Biblioteca responsável:
WPRO
ABSTRACT
Allergic rhinitis is the most common chronic disease worldwide. Various upper airway symptoms lower quality of life, and due to the recurrent symptoms, multiple treatments are usually attempted rather than one definitive treatment. There are alternatives to medical (medication-based) and nonmedical treatments. A guideline is needed to understand allergic rhinitis and develop an appropriate treatment plan. We have developed guidelines for medical treatment based on previous reports. The current guidelines herein are associated with the “KAAACI Evidence-Based Guidelines for Allergic Rhinitis in Korea, Part 1: Update in pharmacotherapy” in which we aimed to provide evidence-based recommendations for the medical treatment of allergic rhinitis. Part 2 focuses on nonpharmacological management, including allergen-specific immunotherapy, subcutaneous or sublingual immunotherapy, nasal saline irrigation, environmental management strategies, companion animal management, and nasal turbinate surgery. The evidence to support the treatment efficacy, safety, and selection has been systematically reviewed. However, larger controlled studies are needed to elevate the level of evidence to select rational non-medical therapeutic options for patients with allergic rhinitis.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Allergy, Asthma & Respiratory Disease
Ano de publicação:
2023
Tipo de documento:
Article